Drug Profile
Infliximab biosimilar - Sunshine Guojian Pharmaceutical
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Shanghai CP Guojian Pharmaceutical
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 01 Dec 2011 Discontinued - Phase-III for Rheumatoid arthritis in China (IV)
- 01 Dec 2008 Phase-III clinical trials in Rheumatoid arthritis in China (IV)